drugset / Trial / NCT01844583
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
Timeline
- Start
- 2013-06-25
- Primary completion
- 2014-08-04
- Completion
- 2016-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alisertib | Small molecule | 50 mg | Oral |
| Subject | Esomeprazole | Small molecule | 40 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |